Hong Paul, Tammareddi Neelima, Walvekar Rohan, Chiu Ernest S, Poole Jeffrey C, Kluka Evelyn A, Simon Lawrence M
IWK Health Centre, Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, NS, Canada.
Int J Pediatr Otorhinolaryngol. 2013 Jul;77(7):1194-7. doi: 10.1016/j.ijporl.2013.04.038. Epub 2013 May 23.
Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear.
The objective of this study is to determine the duration of treatment and age at which propranolol may be successfully discontinued in children with infantile hemangiomas of the head and neck.
A review of all patients presenting to a pediatric vascular anomalies clinic from January 2008 to December 2011 was performed. Those with head and neck infantile hemangiomas who completed propranolol therapy were included. Each patient's records were reviewed for demographics, clinical response to propranolol, age at discontinuation of propranolol, and adverse events.
Forty-five patients were included for review (mean age at presentation, 3.5 months) with all demonstrating positive responses. The mean age at discontinuation of propranolol was 11.8 months of age (range, 8-15 months) with a mean treatment duration of 6.5 months (range, 3-11 months). No recurrences were noted over a mean follow-up period of 19.9 months (range, 10-28 months).
Discontinuation of propranolol at approximately 12 months of age was found to be appropriate in our study population.
尽管普萘洛尔可作为头颈部婴幼儿血管瘤的一种有效的一线药物治疗方法，但治疗持续时间及停用普萘洛尔的时机尚不清楚。
本研究的目的是确定头颈部婴幼儿血管瘤患儿的治疗持续时间以及成功停用普萘洛尔的年龄。
对2008年1月至2011年12月到小儿血管异常门诊就诊的所有患者进行回顾性研究。纳入完成普萘洛尔治疗的头颈部婴幼儿血管瘤患者。查阅每位患者的记录，了解其人口统计学资料、对普萘洛尔的临床反应、停用普萘洛尔时的年龄以及不良事件。
45例患者纳入回顾性研究（就诊时平均年龄3.5个月），所有患者均显示出阳性反应。停用普萘洛尔时的平均年龄为11.8个月（范围8 - 15个月），平均治疗持续时间为6.5个月（范围3 - 11个月）。在平均19.9个月（范围10 - 28个月）的随访期内未发现复发。
在我们的研究人群中，发现约12个月大时停用普萘洛尔是合适的。
